Literature DB >> 11157080

Transplantation of cryopreserved adult human Schwann cells enhances axonal conduction in demyelinated spinal cord.

I Kohama1, K L Lankford, J Preiningerova, F A White, T L Vollmer, J D Kocsis.   

Abstract

Schwann cells derived from human sural nerve may provide a valuable source of tissue for a cell-based therapy in multiple sclerosis. However, it is essential to show that transplanted human Schwann cells can remyelinate axons in adult CNS and improve axonal conduction. Sections of sural nerve were removed from amputated legs of patients with vascular disease or diabetes, and Schwann cells were isolated and cryopreserved. Suspensions of reconstituted cells were transplanted into the X-irradiation/ethidium bromide lesioned dorsal columns of immunosuppressed Wistar rat. After 3-5 weeks of extensive remyelination, a typical Schwann cell pattern was observed in the lesion zone. Many cells in the lesion were immunopositive for an anti-human nuclei monoclonal antibody. The dorsal columns were removed and maintained in an in vitro recording chamber; the conduction properties were studied using field potential and intra-axonal recording techniques. The transplanted dorsal columns displayed improved conduction velocity and frequency-response properties, and action potentials conducted over a greater distance into the lesion, suggesting that conduction block was overcome. These data support the conclusion that transplantation of human Schwann cells results in functional remyelination of a dorsal column lesion.

Entities:  

Mesh:

Year:  2001        PMID: 11157080      PMCID: PMC2605383     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  28 in total

1.  Spinal cord multiple sclerosis lesions in Japanese patients: Schwann cell remyelination occurs in areas that lack glial fibrillary acidic protein (GFAP).

Authors:  Y Itoyama; A Ohnishi; J Tateishi; Y Kuroiwa; H D Webster
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

2.  Restoration of secure conduction by central demyelination.

Authors:  K J Smith; W I McDonald; W F Blakemore
Journal:  Trans Am Neurol Assoc       Date:  1979

3.  Remyelination of CNS axons by Schwann cells transplanted from the sciatic nerve.

Authors:  W F Blakemore
Journal:  Nature       Date:  1977-03-03       Impact factor: 49.962

4.  Intra-axonal recordings in rat dorsal column axons: membrane hyperpolarization and decreased excitability precede the primary afferent depolarization.

Authors:  J D Kocsis; S G Waxman
Journal:  Brain Res       Date:  1982-04-22       Impact factor: 3.252

5.  Depolarizing afterpotentials in myelinated axons of mammalian spinal cord.

Authors:  A R Blight; S Someya
Journal:  Neuroscience       Date:  1985-05       Impact factor: 3.590

6.  Intracellular recording from vertebrate myelinated axons: mechanism of the depolarizing afterpotential.

Authors:  E F Barrett; J N Barrett
Journal:  J Physiol       Date:  1982-02       Impact factor: 5.182

7.  Absence of potassium conductance in central myelinated axons.

Authors:  J D Kocsis; S G Waxman
Journal:  Nature       Date:  1980-09-25       Impact factor: 49.962

8.  Suppression of remyelination in the CNS by X-irradiation.

Authors:  W F Blakemore; R C Patterson
Journal:  Acta Neuropathol       Date:  1978-05-24       Impact factor: 17.088

9.  The use of cultured autologous Schwann cells to remyelinate areas of persistent demyelination in the central nervous system.

Authors:  W F Blakemore; A J Crang
Journal:  J Neurol Sci       Date:  1985-09       Impact factor: 3.181

10.  Remyelination in multiple sclerosis.

Authors:  J W Prineas; F Connell
Journal:  Ann Neurol       Date:  1979-01       Impact factor: 10.422

View more
  34 in total

1.  Soluble Neuregulin and Schwann Cell Myelination: a Therapeutic Potential for Improving Remyelination of Adult Axons.

Authors:  Neeraja Syed; Haesun A Kim
Journal:  Mol Cell Pharmacol       Date:  2010

2.  Remyelination of the spinal cord following intravenous delivery of bone marrow cells.

Authors:  Yukinori Akiyama; Christine Radtke; Osamu Honmou; Jeffery D Kocsis
Journal:  Glia       Date:  2002-09       Impact factor: 7.452

3.  Soluble neuregulin-1 has bifunctional, concentration-dependent effects on Schwann cell myelination.

Authors:  Neeraja Syed; Kavya Reddy; David P Yang; Carla Taveggia; James L Salzer; Patrice Maurel; Haesun A Kim
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

4.  Efficient generation of schwann cells from human embryonic stem cell-derived neurospheres.

Authors:  Lina Ziegler; Sergei Grigoryan; In Hong Yang; Nitish V Thakor; Ronald S Goldstein
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

Review 5.  Cell therapy in demyelinating diseases.

Authors:  Claire Rice; Christopher Halfpenny; Neil Scolding
Journal:  NeuroRx       Date:  2004-10

6.  Integration of engrafted Schwann cells into injured peripheral nerve: axonal association and nodal formation on regenerated axons.

Authors:  Christine Radtke; Yukinori Akiyama; Karen L Lankford; Peter M Vogt; Diane S Krause; Jeffery D Kocsis
Journal:  Neurosci Lett       Date:  2005-10-21       Impact factor: 3.046

7.  Remyelination of spinal cord axons by olfactory ensheathing cells and Schwann cells derived from a transgenic rat expressing alkaline phosphatase marker gene.

Authors:  Yukinori Akiyama; Karen Lankford; Christine Radtke; Charles A Greer; Jeffery D Kocsis
Journal:  Neuron Glia Biol       Date:  2004-02

Review 8.  Strategies for achieving and monitoring myelin repair.

Authors:  Claire Rice; Neil Scolding
Journal:  J Neurol       Date:  2007-03-07       Impact factor: 4.849

Review 9.  Cellular transplantation strategies for spinal cord injury and translational neurobiology.

Authors:  Paul J Reier
Journal:  NeuroRx       Date:  2004-10

Review 10.  Prospects for neural stem cell-based therapies for neurological diseases.

Authors:  Jaime Imitola
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.